ArticleBlood2010
In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2.
Article in Blood, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 137 citations in OpenAlex.
- High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients.British journal of haematology · 2026Article
- Perioperative considerations for patients with multiple myeloma.European journal of anaesthesiology and intensive care · 2026Review
- Should monitoring guidelines and decision to treat for IgM MGUS be different when caring for Jehovah's Witness patients?Clinical hematology international · 2026Article
- Prognostic potential of albumin to fibrinogen ratio in multiple myeloma patients.Annals of hematology · 2025Article
- Transcriptional analysis of BMP2 and BMP6 in patients with newly diagnosed multiple myeloma.Oncology letters · 2025Article
- Splenic T2 signal intensity loss on MRI is associated with disease burden in multiple myeloma.European radiology · 2025Article
- Rare case of pure red cell aplasia secondary to smoldering multiple myeloma successfully treated with daratumumab - case report and review of the literature.Annals of hematology · 2025Review
- Ferroptosis: a novel pharmacological mechanism against multiple myeloma.Frontiers in pharmacology · 2025Review
- Article
- Article
- LILRB4 regulates multiple myeloma development through STAT3-PFKFB1 pathway.Cell death & disease · 2024Article
- HIF2α, Hepcidin and their crosstalk as tumour-promoting signalling.British journal of cancer · 2023Review
- Synergistic immunotherapy targeting cancer-associated anemia: prospects of a combination strategy.Cell communication and signaling : CCS · 2023Review
- Pulmonary hypertension in patients with multiple myeloma: A comprehensive review.Pulmonary circulation · 2023Review
- The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma.BMC cancer · 2023Article
- Hepcidin and Iron in Health and Disease.Annual review of medicine · 2023Review
- The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment.Medicina (Kaunas, Lithuania) · 2022Article
- Thalidomide affects limb formation and multiple myeloma related genes in human induced pluripotent stem cells and their mesoderm differentiation.Biochemistry and biophysics reports · 2021Article
- High Carbohydrate Diet Is Associated with Severe Clinical Indicators, but Not with Nutrition Knowledge Score in Patients with Multiple Myeloma.International journal of environmental research and public health · 2021Article
- The Role of Iron in Cancer Progression.Frontiers in oncology · 2021Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors at 8 institutions in 3 countries.
Funding
Abstract
Hepcidin is the principal iron-regulatory hormone and a pathogenic factor in anemia of inflammation. Patients with multiple myeloma (MM) frequently present with anemia. We showed that MM patients had increased serum hepcidin, which inversely correlated with hemoglobin, suggesting that hepcidin contributes to MM-related anemia. Searching for hepcidin-inducing cytokines in MM, we quantified the stimulation of hepcidin promoter-luciferase activity in HuH7 cells by MM sera. MM sera activated the hepcidin promoter significantly more than did normal sera. We then examined the role of bone morphogenetic proteins (BMPs) and interleukin-6 (IL-6), the major transcriptional regulators of hepcidin. Mutations in both BMP-responsive elements abrogated the activation dramatically, while mutations in the IL-6-responsive signal transducer and activator of transcription 3-binding site (STAT3-BS) had only a minor effect. Cotreatment with anti-BMP-2/4 or noggin-Fc blocked the promoter induction with all MM sera, anti-IL-6 blocked it with a minority of sera, whereas anti-BMP-4, -6, or -9 antibodies had no effect. BMP-2-immunodepleted MM sera had decreased promoter stimulatory capacity, and BMP-2 concentrations in MM sera were significantly higher than in normal sera. Our results demonstrate that BMP-2 is a major mediator of the hepcidin stimulatory activity of MM sera.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.